East Windsor, NJ—Sabinsa’s Curcumin C3 Complex with BioPerine was used as adjuvant therapy for COVID-19 in a double-blind, randomized, controlled clinical trial conducted on COVID-19 patients in India, according to a press release.
The trial involved a total of 140 patients with mild, moderate, and severe symptoms of COVID-19. Patients who received the C3 Complex showed quicker symptomatic recovery; had a lower incidence of red-flag signs; and had a better ability to maintain oxygen saturation >94% on room air only. D-dimer levels were less severe in the C3 group than in the non-C3 group. Some patients in the moderate non-C3 group required Tocilizumab injections; no patients in the moderate C3 group, however, required that intervention. Fewer in the C3 group needed mechanical ventilator support or suffered thromboembolic episodes than in the non-C3 group.
The paper, published in Frontiers in Pharmacology, concluded that that the oral curcuminoids + piperine combination as adjuvant therapy in COVID-19 treatment could reduce morbidity and mortality.
“While larger trials will be needed to establish the findings of the study on a firmer footing, it is gratifying to learn of these promising preliminary results,” said Dr. Muhammed Majeed, Founder and Chairman of Sami-Sabinsa group, in the press release.